Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Fresh questions over DLL3
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
CD19 is worth $700m to Merck
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Agenus looks to new deals and an ex-US path
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
